Virtually all study participants were white Danish men, and the median age at baseline was similar for men with prostate cancer and those without it (age 68 and 69 years, respectively). Their findings were then applied to the general male population aged 40 to 80 years living in Denmark from 1997 through 2006 (n= 5 1,351,441). The goals of the study were to examine individual changes in PSA over a long time interval, and determine whether these changes were associated with prostate cancer risk and mortality beyond what is predicted by total PSA. Among 7455 men in the Copenhagen City Heart Study, they identified 503 men (121 with prostate cancer 382 matched control subjects) aged 30 to 80 years with repeated PSA measurements taken over 20 years. Ørsted and colleagues reported on whether long-term PSAV improves classification of prostate cancer risk and mortality. Ørsted DD, Bojesen SE, Kamstrup PR, Nordestgaard BG.Įur Urol.
Long-term Prostate-specific Antigen Velocity in Improved Classification of Prostate Cancer Risk and Mortality 5 Recently, Ørsted and colleagues 6 and Wallner and associates 7 evaluated the value of PSAV as an adjunct marker to PSA, its role in predicting aggressive disease, and improving classification of prostate cancer risk and mortality. 2, 3 Conversely, other studies have shown that PSAV has limited value 4 and biopsying men with high PSAV but no other indication would lead to a large number of additional prostate biopsies. Some prior studies have shown that a PSAV provides independent predictive information for estimating prostate cancer risk 1 and a PSAV threshold of 0.35 to 0.4 ng/mL/year has been associated with the likelihood of insignificant prostate cancer, suggesting that PSAV may increase specificity for identifying patients with clinically significant disease. The change in PSA level over time, PSA velocity (PSAV), is such a marker that may improve specificity however, its role as an adjunct to PSA is controversial. Since the introduction of widespread prostate-specific antigen (PSA)-based prostate cancer screening, several markers have been employed to aid in detection of prostate cancer.
0 kommentar(er)
